-
It is widely accepted that vulnerable patients are best protected from acquiring invasive mold diseases by placing them in a protected environment, supplying sterile air by means of HEPA filtration with or without laminar air flow (LAF). However, there is little to support this contention.
-
TNF Blockers: Should You Be Concerned?; FDA Actions
-
Seybolt and colleagues performed a retrospective analysis of refugees seen as part of a 2-visit health evaluation at Boston Medical Center from October 1998 through May 2002.
-
At the University of Pittsburgh Medical Center, laboratory-based surveillance of coagulase-negative staphylococci found that 4% were linezolid resistant. MIC's to linezolid were generally > 256 ug/mL; the isolates were all susceptible to vancomycin and daptomycin.
-
This paper presents the results of a retrospective cohort analysis from the Mayo Clinic of 79 patients with bacterial spine infection who underwent baseline and follow-up imaging studies with MRI.
-
Within the past few months, gatifloxacin (Tequin®) has received some attention in the medical community due to reports of serious hypoglycemia and hyperglycemia.
-
Air Travel and DVT Risk: Is Hypobaric Hypoxia the Culprit?; GERD: Size Matters; Does aTNFa for RA Increase Infections and Malignancies?; Postexposure Treatment with Doxycycline and Tick-Borne Relapsing Fever; Secondary Prevention of Stroke: Persistence Pays Off; That Darned Cold Sore: What a Difference a Day Makes!
-
The introduction of therapy animals and pets in the health care setting has created unique opportunities and challenges for infection control personnelproblems that DiSalvo and colleagues point out can be blurred by confusion between various animal programs.
-
Daptomycin is a cyclic lipopeptide antibiotic which was initially approved by the Food and Drug Administration (FDA) for the treatment of complicated skin and skin-skin structure infections in September 2003.
-
Over 63,000 healthy infants from 11 latin american countries and Finland were randomized to receive either 2 oral doses of a live, attenuated human rotavirus vaccine or placebo at 2 and 4 months of age.